Generate Biomedicines (NASDAQ:GENB) Shares Gap Up - Here's What Happened

Key Points

• Generate Biomedicines shares jumped at the open, rising from a prior close of $13.21 to $13.87 and later trading near $14.96 on volume of about 310,000 shares.
• Analyst sentiment is mixed but leans positive: six analysts rate the stock Buy, one Hold and one Sell, producing a “Moderate Buy” consensus and an average price target of $26.40. HC Wainwright maintained its Buy rating with a $30 target.
• The company recently reported a quarterly loss of $0.52 per share, worse than the $0.48 consensus estimate, on $6.31 million in revenue. Several institutional investors, including Braidwell and Banque Pictet, have recently initiated sizable positions.

Generate Biomedicines Inc (NASDAQ:GENB - Get Free Report)'s stock price gapped up before the market opened on Wednesday. The stock had previously closed at $13.21, but opened at $13.87. Generate Biomedicines shares last traded at $14.9610, with a volume of 310,057 shares changing hands.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. Wall Street Zen lowered shares of Generate Biomedicines from a "hold" rating to a "sell" rating in a research note on Saturday, October 17th. Weiss Ratings upgraded Generate Biomedicines from a "sell (d)" rating to a "sell (d+)" rating in a research note on Friday, September 25th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $30.00 target price on shares of Generate Biomedicines in a report on Monday, October 5th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $26.40.

Generate Biomedicines Stock Performance

The firm has a market capitalization of $1.86 billion and a P/E ratio of -9.36. The business has a fifty day moving average of $15.07 and a 200-day moving average of $14.14.

Generate Biomedicines (NASDAQ:GENB - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.04). The business had revenue of $6.31 million during the quarter. On average, equities research analysts forecast that Generate Biomedicines Inc will post -2.29 earnings per share for the current fiscal year.

Institutional Trading of Generate Biomedicines

A number of hedge funds and other institutional investors have recently made changes to their positions in GENB. Braidwell LP acquired a new stake in shares of Generate Biomedicines in the 2nd quarter worth approximately $55,398,000. Banque Pictet & Cie SA bought a new stake in Generate Biomedicines during the third quarter worth approximately $26,631,000. State Street Corp bought a new stake in Generate Biomedicines during the second quarter worth approximately $8,883,000. The Manufacturers Life Insurance Company acquired a new stake in Generate Biomedicines in the second quarter worth approximately $1,431,000. Finally, Bank Pictet & Cie Europe AG acquired a new stake in Generate Biomedicines in the third quarter worth approximately $1,168,000.

About Generate Biomedicines

Generate Biomedicines is a biotechnology company that uses generative artificial intelligence, machine learning and protein engineering to design novel protein-based medicines. Its platform is intended to identify and develop therapeutic proteins with desired biological properties, potentially shortening the time required to discover new drug candidates.

The company's research activities focus on applying computational biology and laboratory experimentation to create medicines for a range of diseases, including conditions in immunology, inflammation, oncology and other areas of significant unmet medical need.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.